The Contribution of Lp-PLA2 Level to the Presence of Coronary Plaques in Patients With Non Alcoholic Fatty Liver Disease

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT01139632

Acronym

0030-10

Enrollment

Registered

2010-06-08

Start date

2010-07-31

Completion date

2011-03-31

Last updated

2011-04-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Coronary Artery Disease, Nonalcoholic Fatty Liver Disease

Keywords

NAFLD, lP-pla2, Coronary Arthery Disease

Brief summary

The most common cause of death in patients with NAFLD(Nonalcoholic Fatty Liver Disease) is CAD(Coronary Artery Disease). NAFLD patients have 65% more mortality than general population. The aim of the investigators study is to diagnose early coronary artery disease in NAFLD patient by measuring of PLA2. The investigators expect that PLA2 will higher in patients with patients with combination of CAD, unstable plaque and NAFLD.

Detailed description

Background: The most common cause of death in patients with NAFLD(Nonalcoholic Fatty Liver Disease) is CAD(Coronary Artery Disease). NAFLD patients have 65% more mortality than general population. The aim of our study is to diagnose early coronary artery disease in NAFLD patient by measuring of PLA2. Methods: 60 patients with chest pain and low to intermediate risk for coronary events will undergo Cardiac CT and blood test measurement of enzyme PLA2, markers of inflammation: CRP, MDA(Malondialdehide), Paraoxonase, FFA(Free Fatty Acids), TG(Triglycerids) will performed. CAD is defined as a stenosis of more than 50% in at least one major coronary artery, unstable plaque defined as low attenuated plaque \<30HU and fatty liver defined as difference in liver and spleen attenuation value -10HU by using CT. Expected results : we expect that PLA2 will higher in patients with patients with combination of CAD, unstable plaque and NAFLD.

Interventions

None listed

Study design

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

1. Patients at intermediate risk for significant CAD was admitted to the hospital with the diagnosis of chest pain or undergoing elective CT coronarography due to suspection of coronary artery disease. 2. Male and female 18years or older. 3. Able to provide written informed consent. Intermediate Risk patients for having significant CAD is deﬁned as: * chest pain or dyspnea in the presence of negative stress tests; * the absence of chest pain but positive stress tests; * the absence of chest pain and of positive stress tests but intermittent arrhythmias

Exclusion criteria

1. Acute coronary syndrome presentation: * ST segment deviation on ECG and/or 2. Cardiac troponin elevation. 3. Chest pain in combination with positive tests for myocardial ischemia 4. Hemodynamic instability on presentation. 5. Inability to write inform consent. 6. Age \<18 years. 7. Participation in an investigational study within the previous 30days.

Countries

Israel

Outcome results